US2019225664A1PendingUtilityA1

Antagonists of activin-actriia and uses for increasing red blood cell levels

61
Assignee: ACCELERON PHARMA INCPriority: Dec 18, 2006Filed: Sep 4, 2018Published: Jul 25, 2019
Est. expiryDec 18, 2026(~0.4 yrs left)· nominal 20-yr term from priority
Inventors:Matthew L. ShermanJasbir SeehraNiels Borgstein
A61P 35/00A61P 7/06A61K 38/00A61K 38/1709C07K 2319/30C07K 2319/31A61P 13/12C07K 16/00C07K 14/71A61K 38/22C07K 14/495C07K 16/22
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

Claims

exact text as granted — not AI-modified
1 - 32 . (canceled) 
     
     
         33 . A method for identifying an agent that stimulates production of red blood cells, the method comprising:
 a) identifying a test agent that binds to activin or a ligand-binding domain of an ActRIIa polypeptide; and   b) evaluating the effect of the agent on the levels of red blood cells, hemoglobin, and/or red blood cell precursor levels.   
     
     
         34 . The method of  claim 33 , wherein the agent is selected from the group consisting of non-peptidyl organic molecules, peptides, polypeptides, peptidomimetics, sugars, hormones, and nucleic acid molecules. 
     
     
         35 . The method of  claim 33 , wherein the agent is identified by a biochemical method. 
     
     
         36 . The method of  claim 33 , wherein the agent is identified by a mechanism based assay. 
     
     
         37 . The method of  claim 33 , wherein the agent is evaluated in a cell based assay. 
     
     
         38 . The method of  claim 33 , wherein the agent is evaluated in an in vivo assay. 
     
     
         39 . The method of  claim 33 , wherein the agent is evaluated in an in vitro assay. 
     
     
         40 . The method of  claim 33 , wherein the ActRIIa polypeptide comprises the amino acid sequence of SEQ ID NO: 2. 
     
     
         41 . The method of  claim 33 , wherein the ActRIIa polypeptide comprises the amino acid sequence of SEQ ID NO: 3. 
     
     
         42 . The method of  claim 33 , wherein the ActRIIa polypeptide comprises the amino acid sequence of SEQ ID NO: 7. 
     
     
         43 . The method of  claim 33 , wherein the ActRIIa polypeptide comprises the amino acid sequence of SEQ ID NO: 12. 
     
     
         44 . The method of  claim 33 , wherein the ActRIIa polypeptide consists of the amino acid sequence of SEQ ID NO: 7.

Join the waitlist — get patent alerts

Track US2019225664A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.